Patient reported outcomes to support drug development decision making by Nixon, Annabel et al.
35Farmeconomia. Health economics and therapeutic pathways 2015; 16(2) © SEEd All rights reserved
proved product labels 2006-2010, identified 
that 24% were granted PRO claims [2], with 
a comparison of FDA and EMA labelling 
showing that the EMA is more likely than the 
FDA to approve PRO claims [3]. The majori-
ty of PRO data that is captured does not make 
it onto the regulatory approved label, this is 
particularly noted in oncology [4] which is 
currently being actively addressed by indust-
ry and regulators [5]. PRO data, particularly 
HRQL data, provides essential contextuali-
zing information in oncology so that the qua-
lity of improved survival can be understood 
from patient’s perspective [6,7].
PROs also provide important supporting evi-
dence of treatment benefit that are of value 
to other stakeholders. Increasingly PROs are 
playing a central role in Health Technology 
Agency (HTA) decision making, particularly 
in the UK (National Institute for Clinical 
Excellence, NICE), France (Transparency 
Committee, TC) and Germany (Federal Joint 
Committee, GBA). The increasing role that 
economic evaluation plays in reimbursement 
decision making brings PROs to the forefront 
of HTA decision making as reimbursement 
agencies seek value propositions that go 
beyond traditional safety and clinical effica-
cy messages. Due to the rising costs of health 
care and the increased demand to demonstra-
te value for money, pharmaceutical compa-
nies are now charged with generating eviden-
ce on the patient’s perspective of treatment. 
The patient’s perspective is often expressed 
in the form of health utilities, a measure of 
satisfaction with a particular state of health, 
and PRO instruments (such as the EQ-5D-
5L, SF-6D) allow utilities to be derived from 
patients. Non-utility PRO data are increasin-
gly valued by payors with recognition that 
they directly reflect the patient experience of 
a disease and its treatment, and contribute to 
a more holistic understanding of the poten-
IntroductIon
Patient reported outcomes (PROs), a me-
asurement based on a report that comes di-
rectly from the patient about the status of 
their health condition without amendment or 
interpretation of the patient’s response by a 
clinician or anyone else [1], are playing an 
increasingly central role in drug development 
decision making. PRO instruments are avai-
lable to measure signs and symptoms of dise-
ase, functioning (physical, cognitive, psycho-
logical, emotional), treatment satisfaction, 
activities of daily living and health-related 
quality of life (HRQL), amongst others. Valid 
and reliable PRO instruments are able to pro-
vide a standardized, quantifiable measure of 
treatment benefit, upon which the outcomes 
of interventions and treatment effect from the 
patient’s perspective can be judged. In some 
instances, PROs provide the best evidence of 
a treatment’s effectiveness, for example when 
evaluating treatments for pain, gastrointesti-
nal and urological symptoms, or psychologi-
cal well-being. This year the FDA approval 
of eluxadoline for the treatment of adults 
with irritable bowel syndrome with diarrhea 
(IBS-D) was based on a composite primary 
endpoint comprising patient reported daily 
worst abdominal pain score and a reduction 
in average daily stool consistency, with data 
being captured for both endpoints by patients 
in an electronic daily diary.
ApplIcAtIons of pro dAtA
PROs are used in clinical trials to measure 
the effect of an intervention on aspects of tre-
atment relevant to patients. PRO data from 
clinical trials are submitted to regulatory 
agencies, such as the European Medicines 
Agency (EMA) and the US Food and Drug 
Administration (FDA), to support regulatory 
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tial value of a new product. Returning again 
to oncology, payors are increasingly intere-
sted in the quality as well as the duration of 
survival. Recent benefit assessments of the 
national HTA agency in Germany, the GBA 
(Federal Joint Committee), demonstrate how 
lack of such data can compromise pricing 
and reimbursement outcomes. In the asses-
sment of crizotinib in non-small cell lung 
cancer (NSCLC) the manufacturer provided 
additional data during the hearing procedure 
with the GBA that allowed the evaluation of 
patient-reported symptoms and HRQL, the 
assessment was subsequently increased from 
‘no additional benefit proven’ to a ‘hint of 
significant additional benefit’ versus chemo-
therapy in one patient subgroup.
PROs are also used in real world evidence 
or observational studies to capture the im-
pact of a medical intervention on patients 
in real world settings, as well as in clinical 
practice to inform discussions between the 
physician and the patient. In the UK National 
Health Service (NHS) all patients having hip 
or knee replacements, varicose vein surge-
ry, or groin hernia surgery are invited to fill 
in PROs, the data from the instruments are 
used to calculate the health gains after sur-
gical treatment using pre- and post-operative 
surveys. National headline data are published 
every month with more granular data publi-
shed every quarter. This data provides infor-
mation on the effectiveness of care delivered 
to NHS funded patients from the perspective 
of the patients themselves, and complements 
existing information on the quality of NHS 
services.
PROs influence clinicians in prescribing de-
cision making, and influence patient demands 
for treatments, particularly in the US where 
direct-to-consumer advertising is permitted.
chArActerIstIcs of 
pro Instruments
For PRO data to effectively inform decision 
making across all stakeholders, high stan-
dards of data capture and measurement are 
mandatory. PRO instruments are required to 
have proven validity, reliability, and ability 
to detect change (responsiveness). Great care 
has to be taken to ensure that PRO results are 
correctly interpreted, requiring published evi-
dence of benchmarks used to evaluate PRO 
change scores in groups of patients (minimal 
important difference, MID) and individual 
patients (responder analysis). It is increasin-
gly common for PROs to be used in multi-
national studies. For a PRO instrument to be 
considered valid to be used with a population 
who speak a different language than the lan-
guage it was originally developed in, it needs 
to go through a specific translation process 
referred to as linguistic validation, which en-
sures that the translated PRO instrument has 
conceptual and semantic equivalence. The 
evaluation of technology and the rapid global 
penetration of mobile devices within patient 
populations has driven the adoption of elec-
tronic data capture of PROs. Technologies 
used to capture PRO data electronically in-
clude handheld devices, tablets, web-based 
systems, mobile web, interactive voice re-
sponse systems (IVRS) and digital pen. The-
re are substantial guidelines and best practice 
documents to support the use of electronic 
data capture systems in PRO assessment.
conclusIons
Patient reported outcomes can no longer 
be considered secondary to other outcome 
endpoints. Increasingly PRO data brings the 
patient voice to the forefront of decision ma-
king by multiple stakeholders: regulators, 
payors, health care providers, clinicians, pre-
scribers, and increasingly health care consu-
mers. It is almost certain that this is a trend 
set to continue alongside increasing calls for 
patient centeredness. Ultimately this leads to 
a need for PROs to receive the same level of 
attention as other endpoints in terms of selec-
tion, development, data collection, analysis 
and interpretation. The uniqueness of PRO 
data needs to be well understood in order to 
maximize decision outcomes.
These issues are explored in-depth in a publication co-authored by the editorial authors 
[Nixon A, Wild D, Muehlhausen W. Patient Reported Outcomes: an overview. Torino: 
SEEd, 2015] available online at: http://www.edizioniseed.it/ebooks/libri-patient-repor-
ted-outcomes.html and in the major online bookstores (i.e. www.amazon.com, https://
books.google.com/)
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